In last trading session, MoonLake Immunotherapeutics (NASDAQ:MLTX) saw 0.33 million shares changing hands with its beta currently measuring 1.31. Company’s recent per share price level of $39.42 trading at -$0.03 or -0.08% at ring of the bell on the day assigns it a market valuation of $2.53B. That closing price of MLTX’s stock is at a discount of -47.79% from its 52-week high price of $58.26 and is indicating a premium of 20.29% from its 52-week low price of $31.42. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.34 million shares which gives us an average trading volume of 404.66K if we extend that period to 3-months.
For MoonLake Immunotherapeutics (MLTX), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.12. Splitting up the data highlights that, out of 6 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 1 suggested the stock as a Hold whereas 5 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.75 in the current quarter.
MoonLake Immunotherapeutics (NASDAQ:MLTX) trade information
Upright in the red during last session for losing -0.08%, in the last five days MLTX remained trading in the green while hitting it’s week-highest on Tuesday, 04/22/25 when the stock touched $39.42 price level, adding 3.78% to its value on the day. MoonLake Immunotherapeutics’s shares saw a change of -27.20% in year-to-date performance and have moved 2.86% in past 5-day. MoonLake Immunotherapeutics (NASDAQ:MLTX) showed a performance of 2.68% in past 30-days. Number of shares sold short was 6.35 million shares which calculate 14.6 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 67 to the stock, which implies a rise of 41.16% to its current value. Analysts have been projecting 67 as a low price target for the stock while placing it at a high target of 67. It follows that stock’s current price would drop -69.96% in reaching the projected high whereas dropping to the targeted low would mean a loss of -69.96% for stock’s current value.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -319.65% during past 5 years. In 2025, company’s earnings growth rate is likely to be around -59.95% while estimates for its earnings growth in next 5 years are of -26.00%.
MoonLake Immunotherapeutics (NASDAQ:MLTX)’s Major holders
Insiders are in possession of 15.43% of company’s total shares while institution are holding 102.47 percent of that, with stock having share float percentage of 121.17%. Investors also watch the number of corporate investors in a company very closely, which is 102.47% institutions for MoonLake Immunotherapeutics that are currently holding shares of the company. BVF INC/IL is the top institutional holder at MLTX for having 21.75 million shares of worth $956.4 million. And as of 2024-06-30, it was holding 34.7258 of the company’s outstanding shares.
The second largest institutional holder is CORMORANT ASSET MANAGEMENT, LP, which was holding about 8.49 million shares on 2024-06-30. The number of shares represents firm’s hold over 13.5609 of outstanding shares, having a total worth of $373.49 million.
On the other hand, T. Rowe Price Health Sciences Fund, Inc. and Fidelity Select Portfolios-Health Care Portfolio are the top two Mutual Funds which own company’s shares. As of Dec 31, 2024 , the former fund manager was holding 1.56 shares of worth $61.67 million or 2.47% of the total outstanding shares. The later fund manager was in possession of 752.79 shares on Feb 28, 2025 , making its stake of worth around $29.67 million in the company or a holder of 1.19% of company’s stock.
